Indian pharma major to do phase 3 trial of Russian Covid Vaccine |
Russian Direct Investment Fund or RDIF, has partnered Hyderabad-based drugmaker Dr Reddy`s Laboratories to cooperate on clinical trials and distribution of Sputnik V vaccine in India with deliveries for general use potentially beginning late this year. Once regulatory approvals are in place for conducting trials in India, RDIF will supply 100 million doses of the COVID vaccine, developed by Russian researchers, to DRL. The results of Phase 1 and Phase 2 trials with the vaccine were recently published in Lancet, while both India and Russia were in talks to pursue further trials and manufacture the vaccine in India. The Indian Council of Medical Research maintains that Russia has a good track record in the development of vaccines. The Oxford vaccine is also in Phase-3 trials with India`s Serum Institute contracted to produce it and has gone ahead in the race for public use. There are two other Indian vaccines that are being developed and are in Phase I and II stage trials and have shown no significant side-effects yet. Dr Reddy`s will perform Phase 3 clinical trials, where a vaccine is tested on thousands of human beings to establish efficacy and safety, for Sputnik V in India, as required by Indian regulatory norms. RDIF said deliveries could potentially begin in late 2020, subject to completion of successful trials and registration of the vaccine by regulatory authorities in India. The agreement between RDIF and Dr Reddy`s reflects the growing awareness of countries and organisations to have a diversified anti-COVID vaccine portfolio to protect their populations.
|
|
|
|